Morgan Stanley Upgrades Becton Dickinson (BDX) to Overweight
More News related to BDX
- BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call
- Big Brands Aim to Bolster U.S. AIDS Efforts
- BioInformatics, LLC New Report - Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations
- BD and FIND Achieve Milestone in Global Battle Against MDR-TB
- Notable Analyst Rating Changes 6/12: SKS, CSX, SNIC, PBR Upgraded; AKS, ERIC, TWTC, HGSI Downgraded
More News related to Upgrades
- Deutsche Bank Upgrades Symantec (SYMC) to Buy; Compelling Risk/Reward Opportunity
- Bank of Ameria Upgrades Tomkins plc (TKS) to Buy
- RBS Upgrades Banco Santander (STD) to Buy
- Credit Suisse Upgrades China Life Insurance (LFC) to Overweight
- B. Riley Upgrades Popular (BPOP) to Neutral
Morgan Stanley upgrades Becton Dickinson (NYSE: BDX) from Equal Weight to Overweight.
Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide.
Related Categories
UpgradesStocks Mentioned
-41.92Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
